← back to search

Katherine E. Mues

Amgen (United States) · US
Area of research
Surgery · Economics and Econometrics
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Health Systems, Economic Evaluations, Quality of Life, Diabetes, Cardiovascular Risks, and Lipoproteins, and SARS-CoV-2 and COVID-19 Research.
h-index
18
citations
1,741
works
90
NIH funding
primary concept
email

Recent publications

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
JAMA Cardiology 2021cited by 220position: middledoi
Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction
Journal of clinical lipidology 2021cited by 24position: middledoi
Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans
Journal of the American Heart Association 2021cited by 15position: middledoi
Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease
Journal of the American College of Cardiology 2020cited by 93position: middledoi
Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
Journal of the American Heart Association 2020cited by 22position: middledoi
Adherence to Statin Therapy Among US Adults Between 2007 and 2014
Journal of the American Heart Association 2019cited by 151position: middledoi
Ischemic Event Rates in Very-High-Risk Adults
Journal of the American College of Cardiology 2019cited by 54position: middledoi
Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999–2014
Journal of the American Heart Association 2019cited by 41position: middledoi
Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria
Cardiovascular Drugs and Therapy 2019cited by 16position: middledoi
Impact of a Community-Based Lymphedema Management Program on Episodes of Adenolymphangitis (ADLA) and Lymphedema Progression - Odisha State, India
PLoS neglected tropical diseases 2014cited by 36position: firstdoi
Impact of Community-Based Lymphedema Management on Perceived Disability among Patients with Lymphatic Filariasis in Orissa State, India
PLoS neglected tropical diseases 2013cited by 55position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul Muntner · Diagnostics for the Real World (United States)8 papers (2019–2021)Keri L. Monda · Amgen (United States)7 papers (2019–2021)Robert S. Rosenson · Montreal Heart Institute7 papers (2019–2021)Lisandro D. Colantonio · University of Alabama at Birmingham6 papers (2019–2021)Todd M. Brown · Orano (United States)3 papers (2019–2021)Monika M. Safford · Cornell University3 papers (2019–2019)Michael E. Farkouh · Cedars-Sinai Smidt Heart Institute3 papers (2019–2020)Elizabeth A. Jackson · Temple University3 papers (2019–2021)Bharat Poudel · University of Alabama at Birmingham2 papers (2021–2021) · 2 papers (2013–2014)Adam P. Bress · Intermountain Healthcare2 papers (2021–2021)Jordan B. King · Intermountain Healthcare2 papers (2021–2021)LeAnne M. Fox · Centers for Disease Control and Prevention2 papers (2013–2014)Luqin Deng · University of Alabama at Birmingham Hospital2 papers (2019–2019)Yuling Dai · University of Wisconsin–Madison2 papers (2019–2020) · 2 papers (2013–2014)Catherine G. Derington · Outcomes Research Consortium2 papers (2021–2021)Vera Bittner · University of Alabama at Birmingham2 papers (2019–2021) · 1 papers (2020–2020)James Cook · VA Salt Lake City Healthcare System1 papers (2021–2021)